McIlrath & Eck’s Tvardi Therapeutics TVRD Stock Holding History

McIlrath & Eck’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64	Hold	20	–	–	﹤0.01%	1593
2025 Q4	$86	Hold	20	–	–	﹤0.01%	970
2025 Q3	$779	Hold	20	–	–	﹤0.01%	901
2025 Q2	$467	Hold	20	–	–	﹤0.01%	901
2025 Q1	$309	Hold	20	–	–	﹤0.01%	900
2024 Q4	$375	Hold	20	–	–	﹤0.01%	944
2024 Q3	$227	Hold	20	–	–	﹤0.01%	953
2024 Q2	$190	Hold	20	–	–	﹤0.01%	925
2024 Q1	$670	Hold	20	–	–	﹤0.01%	883
2023 Q4	$547	Hold	20	–	–	﹤0.01%	876
2023 Q3	$1.24K	Hold	20	–	–	﹤0.01%	801
2023 Q2	$2.08K	Hold	20	–	–	﹤0.01%	782
2023 Q1	$3.61K	Hold	20	–	–	﹤0.01%	715
2022 Q4	$7.91K	Hold	20	–	–	﹤0.01%	572
2022 Q3	$7K	Hold	20	–	–	﹤0.01%	597
2022 Q2	$7K	Hold	20	–	–	﹤0.01%	576
2022 Q1	$9K	Sell	20 -6	-23%	-$2.46K	﹤0.01%	550
2021 Q4	$12K	Hold	26	–	–	﹤0.01%	515
2021 Q3	$15K	Hold	26	–	–	﹤0.01%	462
2021 Q2	$14K	Buy	26 +6	+30%	+$3.8K	﹤0.01%	470
2021 Q1	$16K	Buy	+20	New	+$13.7K	0.01%	388

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

McIlrath & Eck's TVRD Position: Q1 2026 in Review

McIlrath & Eck held its Tvardi Therapeutics (TVRD) position steady in Q1 2026 at 20 shares worth $64. The position accounts for ﹤0.01% of the portfolio, ranked #1593.

McIlrath & Eck first reported a position in TVRD in Q1 2021 and has held it in 21 quarters since. The position peaked at $16K in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

McIlrath & Eck held 20 shares of Tvardi Therapeutics worth $64 as of Q1 2026.
McIlrath & Eck left its Tvardi Therapeutics share count unchanged in Q1 2026.
Tvardi Therapeutics made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1593 holding.
McIlrath & Eck first reported a position in Tvardi Therapeutics in Q1 2021 and has held it in 21 quarters since.
McIlrath & Eck's Tvardi Therapeutics position peaked at $16K in Q1 2021.
67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.